
    
      The main objective is to evaluate the anti-tumor activity of DS-8201a in three cohorts of
      advanced breast cancer patients:

        -  Cohort 1: HER2 over-expressing (HER2 IHC3+ or HER2 IHC2+/ISH+)

        -  Cohort 2: HER2 low-expressing (IHC1+ or IHC2+/ISH-)

        -  Cohort 3: HER2 non-expressing (IHC0+)
    
  